The National Group of Expertise on Pancreatic Cancer Research (KNEP) consists of nine research groups from Oslo, Bergen and Stavanger. Through a joint 5-years project supported by the Norwegian Cancer Society, the groups have bundled their research activities to improve early diagnostics and treatment of pancreatic cancer.
The aim of our project is to stimulate collaboration across disciplines and institutions, and to join experts in the field of pancreatic cancer in order to strengthen research on this disease. The research groups will exchange data and biomaterials so that complex associations between various aspects of pancreatic cancer can be identified at the individual patient level. We seek to achieve much-needed, concrete progress in the management of pancreatic cancer patients. Through its collaborative network, KNEP will establish a competitive and sustainable research environment for pancreatic cancer in Norway.
The consortium comprises the following nine work packages
The research portfolio of KNEP comprises studies in the central clinical fields of
Surgery
Oncology
Medical Genetics
In addition to laboratory studies on:
Multi-omics characterization of tumor tissue
High-throughput drug screening
Histopathology
Metabolomics
Animal models for pancreatic cancer
The research groups are based in Oslo, Bergen, and Stavanger, and collaborate with patients from all over Norway. The University of Oslo is the host institution for this 5-years project.
May 2020 - April 2025
Stay informed about research and activities conducted by KNEP - the Norwegian Cancer Society’s National Group of Expertise on Pancreatic Cancer Research.
The Project Board of KNEP is grateful for the generous memorial donation by the Voldbakken family. The donation will be used for research into a new model for pancreatic cancer which has been developed by Prof Anders Molven and his group at the University of Bergen. The model attempts to explain how certain genetic changes can lead to the development of pancreatic cancer.
The results of a new study by the Pathology work package were presented at the annual meeting of the Norwegian Pathology Society. The study shows that pathology evaluation of the effect of neoadjuvant treatment of pancreatic cancer, is only reliable if tumour regression is extensive, while lesser degrees of treatment effect cannot be identified with certainty. Maia Blomhoff Holm (to the right on the photograph), who presented the study, was awarded the “Research prize 2024 – best free paper”. Read the publication here.
Stina M. Stålberg, MD, PhD student at Dept. of Cancer Genetics, ICR, Oslo University Hospital and USN (work package: “Omics and biomarkers”) presented a poster with results from a research project on protein levels of KRAS in pancreatic cancer at the Nordic Precision Cancer Medicine, Acta Oncologica Conference, Holmenkollen Park Hotel in Oslo, September 17-19, 2023.
We will get back to you ASAP via email.
